Chemotherapy can save lives, but some of the drugs most effective against cancer can also damage peripheral nerves. The resulting condition, known as chemotherapy-induced peripheral neuropathy, or CIPN, may cause burning pain, numbness, tingling, pins-and-needles sensations, extreme sensitivity to cold, weakness, loss of balance, or difficulty performing tasks that once required little thought. Symptoms often begin in the fingers and toes and may spread upward as treatment continues. For some patients, neuropathy improves after chemotherapy ends. For others, nerve symptoms remain for months or even years and become one of the most persistent reminders of cancer treatment.
Cannabis has attracted growing interest because THC and CBD interact with biological systems involved in pain signaling, inflammation, and nerve function. Marijuana has shown analgesic effects in some forms of peripheral neuropathic pain, and newer research is now testing cannabinoids specifically in people with chemotherapy-related nerve damage. The results are intriguing but far from definitive. A randomized 2025 study of combined CBD and THC found a possible improvement in sensory impairment but no significant reduction in pain, while a Mayo Clinic trial of topical CBD found no benefit over placebo. Current American Society of Clinical Oncology guidelines therefore do not recommend cannabis as an established treatment for CIPN. The evidence is better described as promising in selected areas, mixed overall, and still experimental.
What Is Chemotherapy-Induced Peripheral Neuropathy?
Peripheral nerves carry sensory, motor, and autonomic signals between the brain and spinal cord and the rest of the body. Certain chemotherapy drugs can injure these nerves through different mechanisms. The treatments most frequently associated with CIPN include taxanes such as paclitaxel and docetaxel, platinum drugs such as oxaliplatin and cisplatin, vinca alkaloids such as vincristine, proteasome inhibitors such as bortezomib, and several other anticancer agents. Symptoms differ somewhat by medication. Oxaliplatin, for example, is particularly known for acute cold-triggered sensations in the hands, mouth, and throat as well as cumulative chronic neuropathy. Taxanes commonly produce numbness, tingling, burning, and sensory loss in a stocking-and-glove pattern.
CIPN is not simply another form of cancer pain. The problem originates in damaged or dysfunctional nerves rather than solely in tumors, inflammation, surgery, or bone injury. That distinction helps explain why ordinary pain medicines often work poorly. Neuropathy can also affect function even when pain is relatively mild. Reduced vibration sensation in the feet can impair balance, numb fingers can make buttons or writing difficult, and sensory loss may increase the risk of falls or injuries. The ASCO guideline emphasizes that when neuropathy becomes intolerable or begins interfering significantly with function during active chemotherapy, clinicians may need to consider delaying treatment, reducing the chemotherapy dose, substituting another drug, or stopping the neurotoxic agent, depending on the cancer and treatment goals.
Why Researchers Are Studying Cannabis for CIPN
The endocannabinoid system helps regulate pain signaling throughout the peripheral and central nervous systems. CB1 receptors are abundant in neurological pathways involved in pain perception, while CB2 receptors are found predominantly in peripheral tissues and immune cells. THC activates cannabinoid receptors more directly and produces the characteristic intoxicating effects of marijuana. CBD does not create the same high and acts through a much broader range of molecular pathways. Laboratory research has therefore raised the possibility that cannabinoids could reduce abnormal sensory signaling, mechanical hypersensitivity, inflammation, or other processes involved in chemotherapy-related nerve injury. The National Cancer Institute notes that cannabinoid receptors are present in both central and peripheral pain pathways and that cannabinoid agonists can produce analgesic effects.
Preclinical research has been particularly encouraging. Animal experiments using paclitaxel and other chemotherapy models have found that both THC and CBD can reduce mechanical allodynia—the painful response to normally nonpainful stimulation—and other signs of chemotherapy-induced neuropathy. Yet animal results frequently look stronger than subsequent human trials. The central question is therefore not whether cannabinoids can influence damaged nerves in a laboratory, but whether marijuana produces enough clinically meaningful benefit in cancer patients to outweigh intoxication, dizziness, sedation, drug interactions, and other risks. That question has become easier to examine as prospective human trials have finally begun to appear.
The 2025 Randomized CBD and THC Trial
One of the most important recent studies was published in 2025 by investigators affiliated with the Lankenau Institute for Medical Research, Main Line Health, Thomas Jefferson University, Columbia University Irving Medical Center, Temple University, and other institutions. The randomized, double-blind, placebo-controlled trial enrolled cancer survivors with grade 2 or 3 chemotherapy-induced peripheral neuropathy following taxane- or platinum-based treatment. Participants received gelcaps containing roughly 125 to 136 mg of CBD plus 6 to 11 mg of THC per day or placebo for 12 weeks. Forty-six people were randomized and 43 completed treatment.
The trial’s primary analysis found no statistically significant overall difference between active cannabinoid treatment and placebo across the principal outcomes. Importantly, there was also no significant improvement in pain. A secondary analysis, however, found greater improvement in the sensory portion of the EORTC CIPN questionnaire among participants receiving CBD/THC, with an approximately 10-point greater improvement than placebo. Neurological examination also showed trends toward better light-touch and vibration sensation in the feet. The researchers concluded that the findings justified additional study but stressed that the trial was underpowered because fewer patients enrolled than originally planned. This is exactly the kind of result that deserves attention without being oversold: the combination may affect sensory dysfunction, but it has not yet been proven to be an effective treatment for CIPN pain.
Earlier Nabiximols Research Found a Possible Responder Group
Cannabinoids had been tested for chemotherapy neuropathy years before the newer CBD/THC trial, although in very small numbers. A randomized placebo-controlled crossover pilot study evaluated nabiximols, an oromucosal cannabinoid spray containing THC and CBD, in 16 patients with established chemotherapy-induced neuropathic pain. When researchers analyzed the entire group, nabiximols did not significantly outperform placebo on the primary pain-intensity measure.
The study did uncover an interesting subgroup. Five participants experienced a reduction of at least two points on the 0-to-10 pain scale, with those responders averaging a 2.6-point decline compared with only 0.6 points during placebo treatment. Researchers estimated a number needed to treat of approximately five based on that responder analysis and concluded that a larger trial was justified. ASCO subsequently reviewed the study but determined that the evidence remained inadequate to recommend oral cannabinoids for established CIPN. The guideline also noted adverse effects such as fatigue, dizziness, dry mouth, and nausea.
Does CBD Alone Help Chemotherapy Neuropathy?
CBD has received substantial attention because it lacks the typical intoxicating effects of THC, making it theoretically more practical for patients already dealing with fatigue, cognitive changes, or other cancer-treatment effects. A University of Copenhagen and Zealand University Hospital study explored whether oral CBD might reduce acute neuropathy during chemotherapy. Fifty-four patients receiving oxaliplatin- or paclitaxel-based treatment took 150 mg CBD twice daily—300 mg per day—for eight days beginning the day before chemotherapy. Compared with nonrandomized controls, participants receiving CBD showed smaller changes in high-frequency vibration testing, and patients receiving oxaliplatin reported less cold sensitivity, throat discomfort, and discomfort swallowing cold liquids.
The study was not a randomized placebo-controlled trial, however, and the groups differed in age. It therefore could not establish that CBD prevented neuropathy. The dose also deserves attention: 300 mg of CBD per day is far higher than the amounts contained in many consumer gummies or oils. Current ASCO cannabis guidance specifically recommends that clinicians not advise adults with cancer to use 300 mg or more of oral CBD daily for general symptom burden outside a clinical trial because efficacy has not been established and such doses have been associated with reversible liver-enzyme abnormalities.
Topical CBD Has Not Performed Well in Controlled Testing
Topical CBD seems particularly appealing for CIPN because symptoms usually concentrate in the hands and feet. Initial case reports from clinicians at Sutter Health and Mayo Clinic described patients who believed THC- or CBD-containing creams reduced chemotherapy neuropathy. Those observations encouraged researchers to test a standardized topical product more rigorously.
Mayo Clinic investigators subsequently conducted a randomized, double-blind, placebo-controlled crossover trial involving 40 patients with established CIPN. Participants applied either a CBD-isolate cream or placebo for two weeks and then switched treatments. Researchers measured neuropathy using multiple validated instruments, including the EORTC CIPN20. CBD cream did not improve neuropathy scores compared with placebo, although it was generally well tolerated. The trial is an important reminder that promising patient anecdotes do not always survive controlled testing. At present, there is no convincing evidence that ordinary CBD creams reliably relieve chemotherapy-induced nerve damage.
The Israeli Oxaliplatin Study Raised the Possibility of Prevention
One of the most provocative cannabis-CIPN studies came from Tel Aviv Sourasky Medical Center and Tel Aviv University. Researchers retrospectively examined more than 500 gastrointestinal-cancer patients treated with oxaliplatin-containing chemotherapy. Among them, 248 had used medical cannabis while 265 had not. Grade 2 or 3 neuropathy occurred in 15.3% of cannabis-exposed patients compared with 27.9% of controls. The apparent difference was strongest among patients who had begun cannabis before oxaliplatin treatment. Cannabis users beginning before chemotherapy were also able to receive a larger cumulative oxaliplatin dose.
Those numbers are striking, but the study was retrospective rather than randomized. People who received medical cannabis may have differed from controls in ways researchers could not fully measure, including supportive care, health behaviors, cancer characteristics, medication use, or clinician decision-making. A retrospective association therefore cannot prove that marijuana protected peripheral nerves. ASCO guidelines currently recommend against using cannabinoids for the prevention of CIPN because controlled evidence has not demonstrated sufficient benefit. The Israeli data are better viewed as a hypothesis-generating signal deserving randomized confirmation rather than a reason to begin marijuana before chemotherapy specifically to prevent neuropathy.
What Current Cancer Guidelines Say
The American Society of Clinical Oncology has evaluated CIPN separately from the broader question of cannabis in cancer care. In its guideline on chemotherapy-induced peripheral neuropathy, ASCO concludes that duloxetine is the only medication with sufficient evidence to recommend for established painful CIPN, although the average benefit is modest. The same guideline states that evidence is insufficient to recommend oral cannabinoids for treatment and specifically recommends against cannabinoids as a method of preventing CIPN during neurotoxic chemotherapy.
ASCO’s separate guideline on cannabis and cannabinoids in adults with cancer reaches a similar conclusion. Clinicians are encouraged to discuss cannabis use openly and without judgment, but evidence remains insufficient to recommend cannabinoids for most cancer-treatment toxicities or cancer pain. One clearer exception involves refractory chemotherapy-induced nausea and vomiting, for which certain prescription cannabinoids have a better-established role. Cannabis should also never be substituted for cancer-directed therapy or used with the expectation that it will treat the cancer itself.
Marijuana May Help Other Symptoms Without Repairing Nerve Damage
A patient can experience a worthwhile improvement in quality of life without the underlying nerve injury reversing. THC may reduce pain perception, facilitate sleep, improve appetite, or ease nausea in some individuals. Someone with persistent CIPN who sleeps poorly because their feet burn at night could therefore perceive cannabis as helpful even if neurological testing shows little change in actual sensory nerve function. That distinction helps reconcile why patients sometimes report substantial cannabis benefit while controlled trials find modest or inconsistent changes in objective neuropathy measurements.
The National Cancer Institute acknowledges that randomized trials of inhaled cannabis in other types of peripheral neuropathy have demonstrated pain reductions compared with placebo. Those studies support the broader biological plausibility of cannabinoid analgesia. But diabetic neuropathy, HIV-associated neuropathy, traumatic nerve injury, and chemotherapy-induced neuropathy are not identical diseases. Results from one neuropathic condition cannot simply be transferred to another. The newest CIPN-specific randomized trial is especially informative because it found a signal for improved sensory impairment without a corresponding significant improvement in pain.
THC vs CBD for CIPN
THC currently has stronger evidence for analgesia across neuropathic pain disorders generally, but it carries more neurological side effects. Depending on dose and individual susceptibility, THC can produce dizziness, sedation, impaired concentration, slowed reaction time, anxiety, changes in heart rate, or uncomfortable intoxication. Those effects can be particularly problematic in people whose chemotherapy neuropathy already affects balance or walking. A treatment that modestly reduces burning pain but increases fall risk may not represent a meaningful net benefit.
CBD avoids most THC-like intoxication but is not pharmacologically inactive. High-dose CBD can inhibit liver enzymes used to metabolize prescription medications and can produce elevations in liver enzymes. Cancer patients may simultaneously take chemotherapy, targeted agents, hormonal therapy, anti-nausea medications, anticoagulants, pain medicines, antidepressants, or other drugs with interaction potential. The ASCO cancer guideline therefore encourages clinicians to ask routinely about cannabis and cannabinoid use so potential interactions can be reviewed rather than assuming an over-the-counter CBD product is harmless.
Cannabis During Active Chemotherapy Requires Extra Caution
Using marijuana after cancer treatment is different from beginning cannabis while chemotherapy is still underway. During active treatment, oncologists may be adjusting chemotherapy based on blood counts, liver function, kidney function, neuropathy severity, infection risk, nausea, appetite, and other toxicities. Cannabis-related dizziness, fatigue, appetite changes, vomiting, or sedation could complicate the clinical picture. CBD’s drug-metabolizing effects may also matter more when anticancer medications with narrow therapeutic windows are involved.
For someone developing rapidly worsening neuropathy during chemotherapy, the priority is to tell the oncology team promptly rather than attempting to mask symptoms with cannabis. Neuropathy is dose-limiting for a reason: continuing a neurotoxic drug despite significant nerve injury can produce long-lasting disability. ASCO specifically recommends that clinicians consider dose delays, reductions, substitutions, or discontinuation when neuropathy becomes intolerable or causes functional impairment. Marijuana might alter the perception of symptoms without preventing continued nerve injury.
How Marijuana Compares With Duloxetine and Other CIPN Treatments
Duloxetine remains the best-supported medication for painful CIPN. Randomized trials have shown statistically significant reductions in chemotherapy neuropathic pain, leading ASCO to recommend that clinicians may offer it to patients with established painful CIPN. Even so, the average improvement is limited, and not every patient tolerates or responds to the medication. This therapeutic gap explains much of the interest in cannabinoids.
Other treatments are less firmly established. ASCO has found insufficient evidence to formally recommend gabapentin, pregabalin, tricyclic antidepressants, acupuncture, exercise, or scrambler therapy specifically for CIPN, although some approaches may be considered on an individualized basis and additional studies continue. A 2025 open-label study of 27 cancer survivors also reported improvements in neuropathy symptoms and physical function during treatment with CBD up to 300 mg daily, particularly after multimodal exercise was added. Because there was no placebo control, however, the study cannot establish how much improvement came from CBD, exercise, natural recovery, expectation effects, or their combination.
Final Thoughts on Marijuana for Chemotherapy-Induced Neuropathy
Research on cannabis for chemotherapy-induced peripheral neuropathy has finally progressed beyond animal experiments and isolated anecdotes. A 2025 randomized CBD/THC trial found a potentially meaningful improvement in sensory impairment, although its primary analysis was negative and pain did not improve significantly. Earlier nabiximols research identified a possible subgroup of responders, a retrospective Israeli study associated cannabis use with lower rates of oxaliplatin neuropathy, and nonrandomized CBD research has produced intriguing signals involving acute chemotherapy symptoms. At the same time, the Mayo Clinic randomized trial found no benefit from topical CBD, and none of these findings yet establishes marijuana as standard CIPN therapy.
Current oncology guidance therefore remains appropriately conservative. Cannabis should not be used as a proven method of preventing chemotherapy neuropathy, and evidence is insufficient to recommend oral cannabinoids routinely for established CIPN. Duloxetine remains the only drug specifically supported by ASCO for painful CIPN, while treatment modifications may be necessary when neuropathy develops during chemotherapy.
For patients with persistent neuropathy despite standard approaches, a discussion about medical cannabis may nevertheless be reasonable—particularly where it is legally available and the oncology team can review THC exposure, CBD dose, other medications, balance and fall risk, liver function, and treatment goals. The distinction between reducing pain, improving sleep, improving sensation, and actually preventing nerve injury is crucial. Current research suggests cannabinoids may influence some of those outcomes, but not necessarily all of them. Larger randomized trials will be needed before clinicians can identify which patients benefit, which THC-to-CBD ratios work best, and whether cannabinoids genuinely change the long-term course of chemotherapy-induced nerve damage.
